Filing Details
- Accession Number:
- 0001209191-21-037484
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-06-02 21:49:08
- Reporting Period:
- 2021-06-01
- Accepted Time:
- 2021-06-02 21:49:08
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1557746 | Aclaris Therapeutics Inc. | ACRS | Pharmaceutical Preparations (2834) | 460571712 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1751167 | N. David Gordon | C/O Aclaris Therapeutics, Inc. 640 Lee Road, Suite 200 Wayne PA 19087 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-06-01 | 87,500 | $0.00 | 195,992 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-06-01 | 9,115 | $22.71 | 186,877 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-06-01 | 4,885 | $23.57 | 181,992 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-06-02 | 31,114 | $21.50 | 150,878 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-06-02 | 6,800 | $22.26 | 144,078 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Units | Disposition | 2021-06-01 | 87,500 | $0.00 | 87,500 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021.
- The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.24 to $23.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.33 to $23.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections.
- The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.01 to $21.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.01 to $22.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020.